196 related articles for article (PubMed ID: 16496933)
21. Outcomes and prognostic factors in canine epitheliotropic and nonepitheliotropic cutaneous T-cell lymphomas.
Azuma K; Ohmi A; Goto-Koshino Y; Tomiyasu H; Ohno K; Chambers JK; Uchida K; Namba H; Nagata M; Nagamine E; Nibe K; Irie M; Tsujimoto H
Vet Comp Oncol; 2022 Mar; 20(1):118-126. PubMed ID: 34250731
[TBL] [Abstract][Full Text] [Related]
22. Prevalence of elevated alanine transaminase activity in dogs treated with CCNU (Lomustine)*.
Hosoya K; Lord LK; Lara-Garcia A; Kisseberth WC; London CA; Couto CG
Vet Comp Oncol; 2009 Dec; 7(4):244-55. PubMed ID: 19891695
[TBL] [Abstract][Full Text] [Related]
23. Lomustine and prednisone as a first-line treatment for dogs with multicentric lymphoma: 17 cases (2004-2005).
Sauerbrey ML; Mullins MN; Bannink EO; Van Dorp TE; Kaneene JB; Obradovich JE
J Am Vet Med Assoc; 2007 Jun; 230(12):1866-9. PubMed ID: 17571992
[TBL] [Abstract][Full Text] [Related]
24. Comparison between L-CHOP and an L-CHOP protocol with interposed treatments of CCNU and MOPP (L-CHOP-CCNU-MOPP) for lymphoma in dogs.
Rassnick KM; Bailey DB; Malone EK; Intile JL; Kiselow MA; Flory AB; Barlow LL; Balkman CE; Barnard SM; Waite AH
Vet Comp Oncol; 2010 Dec; 8(4):243-53. PubMed ID: 21062406
[TBL] [Abstract][Full Text] [Related]
25. Clinical outcome and prognosis of dogs with histopathological features consistent with epitheliotropic lymphoma: a retrospective study of 148 cases (2003-2015).
Chan CM; Frimberger AE; Moore AS
Vet Dermatol; 2018 Apr; 29(2):154-e59. PubMed ID: 28983988
[TBL] [Abstract][Full Text] [Related]
26. Canine cutaneous lymphoma.
McKeever PJ; Grindem CB; Stevens JB; Osborne CA
J Am Vet Med Assoc; 1982 Mar; 180(5):531-6. PubMed ID: 7061338
[TBL] [Abstract][Full Text] [Related]
27. Multiple cutaneous histiocytomas treated with lomustine in a dog.
Maina E; Colombo S; Stefanello D
Vet Dermatol; 2014 Dec; 25(6):559-62, e98-9. PubMed ID: 24963782
[TBL] [Abstract][Full Text] [Related]
28. A phase II study to evaluate the toxicity and efficacy of alternating CCNU and high-dose vinblastine and prednisone (CVP) for treatment of dogs with high-grade, metastatic or nonresectable mast cell tumours.
Rassnick KM; Bailey DB; Russell DS; Flory AB; Kiselow MA; Intile JL; Malone EK; Balkman CE; Barnard SM
Vet Comp Oncol; 2010 Jun; 8(2):138-52. PubMed ID: 20579327
[TBL] [Abstract][Full Text] [Related]
29. Survival times in dogs with presumptive intracranial gliomas treated with oral lomustine: A comparative retrospective study (2008-2017).
Moirano SJ; Dewey CW; Wright KZ; Cohen PW
Vet Comp Oncol; 2018 Dec; 16(4):459-466. PubMed ID: 29797768
[TBL] [Abstract][Full Text] [Related]
30. Low apparent risk of CCNU (lomustine)-associated clinical hepatotoxicity in cats.
Musser ML; Quinn HT; Chretin JD
J Feline Med Surg; 2012 Dec; 14(12):871-5. PubMed ID: 22772480
[TBL] [Abstract][Full Text] [Related]
31. Prospective randomized clinical trial assessing the efficacy of Denamarin for prevention of CCNU-induced hepatopathy in tumor-bearing dogs.
Skorupski KA; Hammond GM; Irish AM; Kent MS; Guerrero TA; Rodriguez CO; Griffin DW
J Vet Intern Med; 2011; 25(4):838-45. PubMed ID: 21689156
[TBL] [Abstract][Full Text] [Related]
32. Combination chemotherapy with L-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma.
Saba CF; Thamm DH; Vail DM
J Vet Intern Med; 2007; 21(1):127-32. PubMed ID: 17338160
[TBL] [Abstract][Full Text] [Related]
33. Pulse-Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs.
Burton JH; Venable RO; Vail DM; Williams LE; Clifford CA; Axiak-Bechtel SM; Avery AC; Thamm DH
J Vet Intern Med; 2015; 29(4):1098-104. PubMed ID: 26119008
[TBL] [Abstract][Full Text] [Related]
34. Influence of therapy on the antioxidant status in patients with melanoma.
Gadjeva V; Dimov A; Georgieva N
J Clin Pharm Ther; 2008 Apr; 33(2):179-85. PubMed ID: 18315784
[TBL] [Abstract][Full Text] [Related]
35. Epitheliotropic lymphoma (mycosis fungoides) presenting as blepharoconjunctivitis in an Irish setter.
Donaldson D; Day MJ
J Small Anim Pract; 2000 Jul; 41(7):317-20. PubMed ID: 10976628
[TBL] [Abstract][Full Text] [Related]
36. Frequency and Severity of Neutropenia Associated with Food and Drug Administration Approved and Compounded Formulations of Lomustine in Dogs with Cancer.
Burton JH; Stanley SD; Knych HK; Rodriguez CO; Skorupski KA; Rebhun RB
J Vet Intern Med; 2016; 30(1):242-6. PubMed ID: 26682700
[TBL] [Abstract][Full Text] [Related]
37. LOPP chemotherapy as a first-line treatment for dogs with T-cell lymphoma.
Brown PM; Tzannes S; Nguyen S; White J; Langova V
Vet Comp Oncol; 2018 Mar; 16(1):108-113. PubMed ID: 28508557
[TBL] [Abstract][Full Text] [Related]
38. Combination CCNU and vinblastine chemotherapy for canine mast cell tumours: 57 cases.
Cooper M; Tsai X; Bennett P
Vet Comp Oncol; 2009 Sep; 7(3):196-206. PubMed ID: 19691648
[TBL] [Abstract][Full Text] [Related]
39. Phase II study of 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea (CCNU; NSC-79037) in the treatment of brain tumors.
Fewer D; Wilson CB; Boldrey EB; Enot JK
Cancer Chemother Rep; 1972 Jun; 56(3):421-7. PubMed ID: 19051504
[TBL] [Abstract][Full Text] [Related]
40. Canine Cutaneous Plasmacytosis: 21 Cases (2005-2015).
Boostrom BO; Moore AS; DeRegis CJ; Robat C; Freeman K; Thamm DH
J Vet Intern Med; 2017 Jul; 31(4):1074-1080. PubMed ID: 28514049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
